Your browser doesn't support javascript.
loading
Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
Halfon, Philippe; Ansaldi, Christelle; Penaranda, Guillaume; Chiche, Laurent; Dukan, Patrick; Stavris, Chloé; Plauzolles, Anne; Retornaz, Frédérique; Bourliere, Marc.
Afiliación
  • Halfon P; Research & Development Department, Laboratoire Alphabio, Marseille, France.
  • Ansaldi C; Department of Internal Medicine, Hôpital Européen, Marseille, France.
  • Penaranda G; Department of Internal Medicine, Hôpital Européen, Marseille, France.
  • Chiche L; Research & Development Department, Laboratoire Alphabio, Marseille, France.
  • Dukan P; Department of Internal Medicine, Hôpital Européen, Marseille, France.
  • Stavris C; Department of Internal Medicine, Hôpital Européen, Marseille, France.
  • Plauzolles A; Department of Internal Medicine, Hôpital Européen, Marseille, France.
  • Retornaz F; Research & Development Department, Laboratoire Alphabio, Marseille, France.
  • Bourliere M; Department of Internal Medicine, Hôpital Européen, Marseille, France.
PLoS One ; 16(7): e0254939, 2021.
Article en En | MEDLINE | ID: mdl-34293022
BACKGROUND & AIM: Liver fibrosis screening in primary care population is a major public health issue. The FIB-4 index is a simple non-invasive fibrosis test combining age, transaminases, platelets count, developed for the diagnosis of advanced fibrosis. The aim of our study was to evaluate the interest of liver fibrosis screening using systematic calculation of FIB-4 in routine blood analysis. METHODS: Between December 2018 and May 2019, we conducted a prospective screening of liver fibrosis in 134 158 patients during a medical check-up including routine blood analysis. Among these patients, 29 707 had transaminases and platelets counts available and benefited from an automatic calculation of FIB-4. Results were obtained from 21 French clinical laboratories in the Bouches du Rhône region. RESULTS: Among the 29 707 patients, 2161 (7.3%) had a high risk of advanced fibrosis (FIB-4>2.67). Individual investigation of patients with FIB-4>2.67 allowed to screen 1268 (1268/2161: 58.7%) patients who were not managed for any liver disease. CONCLUSIONS: This work demonstrates the interest of FIB-4 for the screening of liver fibrosis in primary care population. Although additional clinical validation study is required to determine the utility and applicability of Fib-4 to daily practice, our study strongly supports this easy-to-implement strategy using a simple Fib-4 measure resulting from the use of available routine test results.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atención Primaria de Salud / Índice de Severidad de la Enfermedad / Cirrosis Hepática Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atención Primaria de Salud / Índice de Severidad de la Enfermedad / Cirrosis Hepática Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos